FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379281685> ?p ?o ?g. }

• W4379281685 endingPage "6062" @default.
• W4379281685 startingPage "6062" @default.
• W4379281685 abstract "6062 Background: Most patients with R/M SCCHN do not derive durable benefit from standard-of-care anti-PD-1-based therapy. The currently utilized biomarker, PD-ligand-1 combined proportion score is limited by the availability and heterogeneity of tumor samples. There is an unmet need to develop easily accessible peripheral blood-based biomarkers for response to immunotherapy. Methods: We are conducting a prospective multi-center study to identify peripheral blood derived DNA-based methylation biomarkers measured in patients with R/M SCCHN on treatment with FDA-approved anti-PD-1 based therapy. DNA isolated from these samples undergo bisulfite conversion, methylation profiling using Illumina EPIC microarray, and cellular deconvolution to generate peripheral blood immune profiles (PMID 35140201), including granulocytic (g) and monocytic (m) myeloid derived suppressor cell (MDSC) scores. Associations between baseline peripheral blood immune profiles before the start of treatment with progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan Meier curves and Cox proportional hazards models adjusted for age and sex. Additionally, logistic regression models adjusted for age and sex were utilized to investigate the baseline immune profiles between subgroups of patients who received anti-PD-1 monotherapy with durable clinical benefit for at least 1 year (Group A) versus progression or death within 100 days (Group B) from start of therapy. Results: 61 patients with R/M SCCHN who received anti-PD-1 based therapy as of Oct 31, 2022, were eligible for this preliminary analysis. Mean (SD) age of the entire population was 66.4 (11.8) years, 82% were male. gMDSC score was the only immune parameter with a statistically significant association with PFS (HR 2.6 (1.40 – 4.87) independent of age and sex, with higher scores stratified by median value associated with shorter PFS (Median PFS: 75 days vs. 145 days). Memory CD4 T cells, total CD4 T cells, percentage of T regulatory /CD4 cells, and absolute memory B cells were significantly associated with OS in this population, independent of age and sex (Table). Among the subgroup treated with anti-PD-1 monotherapy, Group A with durable benefit (n = 7, 86% male, mean age: 64.7 years) had significantly higher proportion of CD4 naïve/total CD4 cells (p = 0.03), and significantly lower gMDSC (p = 0.015) & mMDSC (p = 0.000049) scores, compared with Group B (n = 27, 78% male, mean age: 66.4 years). Conclusions: Peripheral blood DNA-based epigenetic immune profiling can recognize clinically relevant methylation biomarkers of benefit from anti-PD-1 therapy before the start of treatment. [Table: see text]" @default.
• W4379281685 created "2023-06-05" @default.
• W4379281685 creator A5013850922 @default.
• W4379281685 creator A5023943352 @default.
• W4379281685 creator A5026101063 @default.
• W4379281685 creator A5029777316 @default.
• W4379281685 creator A5033073004 @default.
• W4379281685 creator A5038339911 @default.
• W4379281685 creator A5044045808 @default.
• W4379281685 creator A5046887908 @default.
• W4379281685 creator A5050569417 @default.
• W4379281685 creator A5053039908 @default.
• W4379281685 creator A5080875822 @default.
• W4379281685 creator A5081393377 @default.
• W4379281685 date "2023-06-01" @default.
• W4379281685 modified "2023-09-23" @default.
• W4379281685 title "Peripheral blood epigenetic immune-profiling and survival outcomes with anti-programmed death (PD)-1 based therapy in recurrent/metastatic (R/M) squamous cell carcinoma of head and neck (SCCHN)." @default.
• W4379281685 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.6062" @default.
• W4379281685 hasPublicationYear "2023" @default.
• W4379281685 type Work @default.
• W4379281685 citedByCount "0" @default.
• W4379281685 crossrefType "journal-article" @default.
• W4379281685 hasAuthorship W4379281685A5013850922 @default.
• W4379281685 hasAuthorship W4379281685A5023943352 @default.
• W4379281685 hasAuthorship W4379281685A5026101063 @default.
• W4379281685 hasAuthorship W4379281685A5029777316 @default.
• W4379281685 hasAuthorship W4379281685A5033073004 @default.
• W4379281685 hasAuthorship W4379281685A5038339911 @default.
• W4379281685 hasAuthorship W4379281685A5044045808 @default.
• W4379281685 hasAuthorship W4379281685A5046887908 @default.
• W4379281685 hasAuthorship W4379281685A5050569417 @default.
• W4379281685 hasAuthorship W4379281685A5053039908 @default.
• W4379281685 hasAuthorship W4379281685A5080875822 @default.
• W4379281685 hasAuthorship W4379281685A5081393377 @default.
• W4379281685 hasConcept C121608353 @default.
• W4379281685 hasConcept C126322002 @default.
• W4379281685 hasConcept C143998085 @default.
• W4379281685 hasConcept C203014093 @default.
• W4379281685 hasConcept C2777701055 @default.
• W4379281685 hasConcept C2908647359 @default.
• W4379281685 hasConcept C50382708 @default.
• W4379281685 hasConcept C71924100 @default.
• W4379281685 hasConcept C8891405 @default.
• W4379281685 hasConcept C99454951 @default.
• W4379281685 hasConceptScore W4379281685C121608353 @default.
• W4379281685 hasConceptScore W4379281685C126322002 @default.
• W4379281685 hasConceptScore W4379281685C143998085 @default.
• W4379281685 hasConceptScore W4379281685C203014093 @default.
• W4379281685 hasConceptScore W4379281685C2777701055 @default.
• W4379281685 hasConceptScore W4379281685C2908647359 @default.
• W4379281685 hasConceptScore W4379281685C50382708 @default.
• W4379281685 hasConceptScore W4379281685C71924100 @default.
• W4379281685 hasConceptScore W4379281685C8891405 @default.
• W4379281685 hasConceptScore W4379281685C99454951 @default.
• W4379281685 hasFunder F4320332161 @default.
• W4379281685 hasIssue "16_suppl" @default.
• W4379281685 hasLocation W43792816851 @default.
• W4379281685 hasOpenAccess W4379281685 @default.
• W4379281685 hasPrimaryLocation W43792816851 @default.
• W4379281685 hasRelatedWork W1996150995 @default.
• W4379281685 hasRelatedWork W2023771859 @default.
• W4379281685 hasRelatedWork W2380021556 @default.
• W4379281685 hasRelatedWork W2763883091 @default.
• W4379281685 hasRelatedWork W3031281572 @default.
• W4379281685 hasRelatedWork W3180780036 @default.
• W4379281685 hasRelatedWork W4200608643 @default.
• W4379281685 hasRelatedWork W4291367166 @default.
• W4379281685 hasRelatedWork W4360983034 @default.
• W4379281685 hasRelatedWork W1564894628 @default.
• W4379281685 hasVolume "41" @default.
• W4379281685 isParatext "false" @default.
• W4379281685 isRetracted "false" @default.
• W4379281685 workType "article" @default.